Top

Published in:

01-12-2017 | Geriatric Oncology (AR MacKenzie, Section Editor)

Treatment of Glioblastoma in Older Adults

Authors: Kelly Braun, Manmeet S. Ahluwalia

Published in: Current Oncology Reports | Issue 12/2017

Abstract

Glioblastoma is the most common primary malignant brain tumor diagnosed in the USA and is associated with a poor prognosis. The outcomes in elderly patients (more than 65 years of age) are worse when compared to those younger than age 65 at the time of diagnosis. Older patients are not always offered treatments that would otherwise be considered standard of care due to comorbidities and concerns about toxicity and tolerability. The initial European Organization for Research and Treatment of Cancer study that led to approval of temozolomide in glioblastoma excluded patients more than 70 years of age. This review outlines challenges that arise in the treatment of glioblastoma in the elderly population and discusses results of recent studies that established the role of adjuvant chemotherapy in addition to radiation and surgery. There is evidence that these patients can benefit from a more aggressive and safe resection, from hypofractionated radiation treatments, and from adjuvant temozolomide.

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6). https://doi.org/10.1007/s00401-016-1545-1.

Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34. https://doi.org/10.1002/ana.21521. CrossRefPubMed

Pallis AG, Ring A, Fortpied C, et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol. 2011;22(8):1922–6. https://doi.org/10.1093/annonc/mdq687. CrossRefPubMed

Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-Oncology. 2014;16(11):1459–68. https://doi.org/10.1093/neuonc/nou063. CrossRefPubMedPubMedCentral

Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51. https://doi.org/10.1038/nrneurol.2009.197. CrossRefPubMed

Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296–307. https://doi.org/10.1038/nrc1319. CrossRefPubMed

Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005. https://doi.org/10.1056/NEJMoa043331.

Lalezari S, Chou AP, Tran A, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology. 2013;15(3):370–81. https://doi.org/10.1093/neuonc/nos308. CrossRefPubMedPubMedCentral

Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009;73(18):1509–10. https://doi.org/10.1212/WNL.0b013e3181bf9907. CrossRefPubMedPubMedCentral

10.

Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neuro-Oncol. 2011;102(2):311–6. https://doi.org/10.1007/s11060-010-0324-4. CrossRef

11.

Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131(6):1342–50. https://doi.org/10.1002/ijc.27385. CrossRefPubMed

12.

Lu C, Ward P, Kapoor G, Rohle D. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–8. https://doi.org/10.1038/nature10860.IDH. CrossRefPubMedPubMedCentral

13.

Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neuro-Oncol. 2012;108(1):11–27. https://doi.org/10.1007/s11060-011-0793-0. CrossRef

14.

Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology. 2013. https://doi.org/10.1093/neuonc/not043.

15.

Yuan Y, Qi C, Maling G, et al. TERT mutation in glioma: frequency, prognosis and risk. J Clin Neurosci. 2016;26:57–62. https://doi.org/10.1016/j.jocn.2015.05.066. CrossRefPubMed

16.

Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508. https://doi.org/10.1056/NEJMoa1407279. CrossRefPubMedPubMedCentral

17.

Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma. JAMA Oncol. 2016;2(11):1460. https://doi.org/10.1001/jamaoncol.2016.1373. CrossRefPubMed

18.

Chaichana KL, Garzon-Muvdi T, Parker S, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239–45. https://doi.org/10.1245/s10434-010-1242-6. CrossRefPubMed

19.

Oszvald Á, Güresir E, Setzer M, et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg. 2012;116(2):357–64. https://doi.org/10.3171/2011.8.JNS102114. CrossRefPubMed

20.

• Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774–82. https://doi.org/10.1200/JCO.2013.51.8886. This analysis produced survival models for patients with glioblastoma of various ages and demonstrated relationships between survival and extent of resection, highlighting the importance of surgical resection in the treatment of these tumors. CrossRefPubMedPubMedCentral

21.

• Noorbakhsh A, Tang JA, Marcus LP, et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg. 2014;120(1):31–9. https://doi.org/10.3171/2013.9.JNS13877. This paper demonstrated that elderly patients with glioblastoma are less likely to receive a gross total resection in comparison with younger patients. CrossRefPubMed

22.

Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35. https://doi.org/10.1056/NEJMoa065901. CrossRefPubMed

23.

Hottinger AF, Stupp R, Homicsko K. Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer. 2014;33(1):32–9. https://doi.org/10.5732/cjc.013.10207. CrossRefPubMedPubMedCentral

24.

Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, GRegory Cairncross J. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol. 1994;29(4):835–9. https://doi.org/10.1016/0360-3016(94)90573-8. CrossRef

25.

• Arvold ND, Tanguturi SK, Aizer AA, et al. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol. 2015;92(2):384–9. https://doi.org/10.1016/j.ijrobp.2015.01.017. This study demonstrated that when controlling for the selection bias against patients with a lower performance status, there were no overall survival differences between SRT and HRT when given with concurrent TMZ in elderly patients. CrossRef

26.

Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33(35):4145–50. https://doi.org/10.1200/JCO.2015.62.6606. CrossRefPubMed

27.

Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–8. https://doi.org/10.1200/JCO.2004.06.082. CrossRefPubMed

28.

Chamberlain MC, Recht LD, Glantz M. Regarding “abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial”. J Clin Oncol. 2005;23(7):1587–8. https://doi.org/10.1200/JCO.2005.05.292.CrossRefPubMed

29.

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330. CrossRefPubMed

30.

Alliot C. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer. 2004;101(12):2897–8. https://doi.org/10.1002/cncr.20707. CrossRefPubMed

31.

Gállego Pérez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29(22):3050–5. https://doi.org/10.1200/JCO.2011.34.8086.CrossRefPubMed

32.

• Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. Cancer. 2016;122(2):189–97. https://doi.org/10.1002/cncr.29742. This is a comprehensive review of published evidence regarding glioblastoma care in the elderly. CrossRefPubMed

33.

Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003;97(9):2262–6. https://doi.org/10.1002/cncr.11323. CrossRefPubMed

34.

Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39(4):350–7. https://doi.org/10.1016/j.ctrv.2012.05.008. CrossRefPubMed

35.

•• Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–37. https://doi.org/10.1056/NEJMoa1611977. This study demonstrated that the addition of temozolomide to short-course radiotherapy prolongs survival in elderly patients with glioblastoma without sacrifice in quality of life. CrossRefPubMed

36.

Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26. https://doi.org/10.1016/S1470-2045(12)70265-6. CrossRefPubMed

37.

Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15. https://doi.org/10.1016/S1470-2045(12)70164-X. CrossRefPubMed

38.

Amsbaugh MJ, Yusuf MB, Gaskins J, Burton EC, Woo SY. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: an analysis of the National Cancer Database. https://doi.org/10.1002/cncr.30730.

39.

Perazzoli G, Prados J, Ortiz R, et al. Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. Alonso MM, ed PLoS One 2015;10(10):e0140131. https://doi.org/10.1371/journal.pone.0140131.

40.

Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5. https://doi.org/10.1200/JCO.2008.16.3055. CrossRefPubMed

41.

Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217–22. https://doi.org/10.1212/01.wnl.0000345668.03039.90. CrossRefPubMedPubMedCentral

42.

Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2):142–8. https://doi.org/10.1200/JCO.2010.30.2729. CrossRefPubMed

43.

• Mason M, Laperriere N, Wick W, et al. Glioblastoma in the elderly: making sense of the evidence. Neuro-Oncology Pract. 2016;3(2):77–86. https://doi.org/10.1093/nop/npv027. This is a systematic review of evidence regarding glioblastoma care in the elderly that discusses the role of bevacizumab. CrossRef

44.

Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12). http://clincancerres.aacrjournals.org/content/17/12/4119.short. Accessed April 27, 2017

45.

• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22. https://doi.org/10.1056/NEJMoa1308345. This study assesses the use of bevacizumab in addition to first-line treatment in glioblastoma. CrossRefPubMed

46.

Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. https://doi.org/10.1056/NEJMoa1308573. CrossRefPubMedPubMedCentral

47.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. In: Khasraw M, editor. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 2014. https://doi.org/10.1002/14651858.CD008218.pub3.

48.

Santoni M, Scoccianti S, Lolli I, et al. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neuro-Oncol. 2013;113(3):397–401. https://doi.org/10.1007/s11060-013-1125-3. CrossRef

49.

Boele FW, Douw L, de Groot M, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology. 2013;15(10):1420–8. https://doi.org/10.1093/neuonc/not102. CrossRefPubMedPubMedCentral

50.

Gehring K, Patwardhan SY, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neuro-Oncol. 2012;107(1):165–74. https://doi.org/10.1007/s11060-011-0723-1. CrossRef

51.

Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007;25(4):1035–71. https://doi.org/10.1016/j.ncl.2007.07.015. CrossRefPubMed

Title: Treatment of Glioblastoma in Older Adults
Authors: Kelly Braun
Manmeet S. Ahluwalia
Publication date: 01-12-2017
Publisher: Springer US
Published in: Current Oncology Reports / Issue 12/2017
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-017-0644-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2017

Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia

Reirradiation of Skull Base Tumors With Advanced Highly Conformal Techniques

A Metabolic Therapy for Malignant Glioma Requires a Clinical Measure

Desmoplastic Small Round Cell Tumor Presenting as an Ocular Mass: Unusual Localization and Remarkable Surgical Approach

What’s New in Imaging for Gynecologic Cancer?

B Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer